Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Teva Pharmaceutical Industries ( TEVA) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 1.6%. By the end of trading, Teva Pharmaceutical Industries fell $1.49 (-2.8%) to $51.51 on average volume. Throughout the day, 8,572,770 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 7,284,200 shares. The stock ranged in price between $51.42-$53.46 after having opened the day at $52.72 as compared to the previous trading day's close of $53.00. Other companies within the Health Care sector that declined today were: Puma Biotechnology ( PBYI), down 18.3%, Aquinox Pharmaceuticals ( AQXP), down 15.3%, Ohr Pharmaceutical ( OHRP), down 13.7% and RXi Pharmaceuticals ( RXII), down 12.8%.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $51.2 billion and is part of the drugs industry. Shares are up 32.2% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, Agios Pharmaceuticals ( AGIO), up 27.8%, Questcor Pharmaceuticals ( QCOR), up 18.7%, Idenix Pharmaceuticals ( IDIX), up 12.4% and Flamel Technologies ( FLML), up 8.7% , were all gainers within the health care sector with Sanofi ( SNY) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Howard Schultz to Jim Cramer: Starbucks Stock Is Cheap and Undervalued

Howard Schultz to Jim Cramer: Starbucks Stock Is Cheap and Undervalued

Jim Cramer: Some Industrials Stocks Are Becoming Great Values

Jim Cramer: Some Industrials Stocks Are Becoming Great Values

Jim Cramer: Reports of Attempted Trade Truce With China Are False

Jim Cramer: Reports of Attempted Trade Truce With China Are False

German Automakers Slump After Trump Tweets New Tariff Threat

German Automakers Slump After Trump Tweets New Tariff Threat

Why Chipotle Is Headed to $450 a Share

Why Chipotle Is Headed to $450 a Share